新型合成大麻素AB-CHMINACA与MDMB-CHMICA摄入后的急性不良反应
该前瞻性观察研究纳入44例因摄入合成大麻素至急诊就诊的患者(39男5女,12-48岁),血清和/或尿液经LC-MS/MS分析确认AB-CHMINACA和MDMB-CHMICA。19例存在一种以上合成大麻素,7例检出其他精神活性物质(主要为苯丙胺类)。按中毒严重度评分,轻度4例、中度31例、重度9例。最常见神经精神症状为CNS抑制(n=21,61%)、定向障碍(n=20,45%)、全面性癫痫发作(n=12,27%)、好斗(n=8,18%)和极度激越(n=7,16%);15例(34%)症状持续24小时或更长。作者认为第三代合成大麻素似乎与比早期合成大麻素(如JWH-018)更严重的临床毒性相关,但该观察需在更大规模、经分析确认的第三代合成大麻素滥用队列中证实。
要点
- 44例急诊患者中,AB-CHMINACA在20份血清和21份尿液中检出,MDMB-CHMICA在19份血清和25份尿液中检出,19例存在一种以上合成大麻素。
- 神经精神症状常见:CNS抑制n=21(61%)、定向障碍n=20(45%)、全面性癫痫发作n=12(27%)、好斗n=8(18%)、极度激越n=7(16%)。
- 按中毒严重度评分,轻度4例、中度31例、重度9例;15例(34%)症状持续24小时或更长。
- 7例检出其他精神活性物质(主要为苯丙胺类),其中5例仅在尿液样本中检出。
- 作者认为第三代合成大麻素AB-CHMINACA与MDMB-CHMICA似乎与比早期合成大麻素(如JWH-018)更严重的临床毒性相关,但需更大队列证实。
适用人群与场景
- 因摄入合成大麻素至急诊就诊的患者,年龄12-48岁,共44例(39男5女)。
红旗征与不能漏的情况
- 全面性癫痫发作(n=12,27%)需紧急处理。
- 极度激越(n=7,16%)和好斗(n=8,18%)需紧急处理。
- CNS抑制(n=21,61%)需紧急处理。
- 症状持续24小时或更长见于15例(34%)。
研究设计与关键结果
- 前瞻性观察研究纳入44例急诊患者,血清和/或尿液经LC-MS/MS分析确认合成大麻素。
- AB-CHMINACA在20份血清和21份尿液中检出,MDMB-CHMICA在19份血清和25份尿液中检出。
- 19例存在一种以上合成大麻素;7例检出其他精神活性物质(主要为苯丙胺类),其中5例仅在尿液样本中检出。
- 按中毒严重度评分,轻度4例、中度31例、重度9例。
- 神经精神症状:CNS抑制n=21(61%)、定向障碍n=20(45%)、全面性癫痫发作n=12(27%)、好斗n=8(18%)、极度激越n=7(16%);15例(34%)症状持续24小时或更长。
- 作者认为第三代合成大麻素AB-CHMINACA与MDMB-CHMICA似乎与比早期合成大麻素(如JWH-018)更严重的临床毒性相关,但需更大规模、经分析确认的第三代合成大麻素滥用队列证实。
证据类型、等级与局限
- 证据类型:前瞻性观察研究。
- 局限:作者指出该观察需在更大规模、经分析确认的第三代合成大麻素滥用队列中证实。
对床旁实践的改变
- 急诊接诊疑似合成大麻素中毒患者时,应关注CNS抑制、定向障碍、全面性癫痫发作、好斗和极度激越等神经精神症状,并注意症状可能持续24小时或更长。
- 作者认为第三代合成大麻素AB-CHMINACA与MDMB-CHMICA似乎与比早期合成大麻素(如JWH-018)更严重的临床毒性相关,但该观察需更大规模、经分析确认的第三代合成大麻素滥用队列证实。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
INTRODUCTION: In 2014, the "European Monitoring Centre for Drugs and Drug Addiction" (EMCDDA) reported on 30 novel synthetic cannabinoids (SCs). Among these were indole- and indazole-based valine derivatives with a cyclohexylmethyl side chain (e.g., AB-CHMINACA and MDMB-CHMICA), which represent a new class of SCs.
METHODS: A prospective observational study of patients treated in emergency departments (EDs) after the intake of SCs was conducted. Clinical and laboratory data were combined and reported to a poison control centre. Serum and/or urine samples of ED patients were analyzed using LC-MS/MS.
RESULTS: Forty four patients (39 male, five female, 12-48 years) were included. AB-CHMINACA (MDMB-CHMICA) was identified in 20 (19) serum samples, and in 21 (25) urine samples, respectively. In 19 of the cases, more than one SC was present. Other psychoactive substances (mainly amfetamines) were identified in seven cases, but in five out of these in urine samples only. Based on the Poison Severity Score, severity of poisoning was minor (4), moderate (31) or severe (9). Most frequently reported neuropsychiatric symptoms were CNS-depression (n = 21, 61%), disorientation (n = 20, 45%), generalized seizures (n = 12, 27%), combativeness (n = 8, 18%) and extreme agitation (n = 7, 16%). Duration of symptoms lasting 24 hours or longer occurred in 15 cases (34%).
DISCUSSION: The prevalence of certain neuropsychiatric symptoms was higher in our study than in former reports after the intake of SCs of the aminoalkylindole-type (first generation) SCs. In addition, severe poisoning and duration of symptoms were also higher.
CONCLUSIONS: In this study, the valine derivative AB-CHMINACA and the tert-leucine derivative MDMB-CHMICA ("third generation of SCs") seem to be associated with more severe clinical toxicity than was previously reported in patients exposed to earlier generation SCs such as JWH-018. However, this observation needs to be confirmed with a larger cohort of patients with analytically confirmed abuse of third generation SCs. The rapid turnover of SCs on the drug market together with the occurrence of SCs such as AB-CHMINACA and MDMB-CHMICA is alarming, especially because of the unexpectedly high frequency of neuropsychiatric symptoms.
参考来源
- Hermanns-Clausen M, Müller D, Kithinji J, et al. Acute side effects after consumption of the new synthetic cannabinoids AB-CHMINACA and MDMB-CHMICA. Clin Toxicol (Phila). 2017. PMID: 29072524. doi:10.1080/15563650.2017.1393082
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。